Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Predictors of lymph node positivity in bladder cancer surgery

Salvador Jaime-Casas • 14 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Salvador Jaime-Casas, MD, City of Hope Comprehensive Cancer Center, Duarte, CA, describes clinical and pathological predictors of lymph node positivity in patients with clinically node-negative bladder cancer undergoing radical cystectomy. Lymphovascular invasion and positive surgical margins are key predictors of occult nodal involvement, which is associated with worse recurrence-free and overall survival. Preoperative hydronephrosis also emerged as an independent prognostic factor. These results may help guide perioperative treatment strategies and bladder preservation approaches in this patient population. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Salvador Jaime-Casas

Which patients with urothelial carcinoma benefit the most from ADCs?
0:30
Which patients with urothelial carcinoma benefit the most from ADCs?
Salvador Jaime-Casas • 14 Feb 2025
Evaluating ADC-based combination therapies in urothelial carcinoma
1:13
Evaluating ADC-based combination therapies in urothelial carcinoma
Salvador Jaime-Casas • 14 Feb 2025

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals